Age Rating
4+
Apps in this category do not contain restricted content.
9+
Apps in this category may contain mild or occasional cartoon, fantasy or real-life violence, as well as occasional or mild adult, sexually suggestive or horrifying content and may not be suitable for children under 9 years of age.
12+
Apps in this category may contain occasional mild indecent language, frequent or intense cartoon or real-life violence, minor or occasional adult or sexually suggestive material, and simulated gambling, and may be for children under 12 years of age.
17+
You must be at least 17 years old to access this App.
Apps in this category may contain frequent and intense offensive language; Frequent and intense cartoon, fantasy or realistic violence: frequent and intense adult, scary and sexually suggestive subjects: as well as sexual content, nudity, tobacco, alcohol and drugs, may not be suitable for children under 17 years of age.
BI News Capturas de tela
BI News CartazBI News Cartaz
BI News CartazBI News Cartaz

About BI News

The BI News app allows all Boehringer Ingelheim employees globally to read BI news from Germany and other regions in German and English. News channels can be subscribed to and are listed in the personalized news listing. News can be filtered by channel. With the implemented search function articles can be searched. Push notification can be activated to make sure not to miss any important news.
Show More

Novidades da Última Versão 1.6.3

Last updated on Aug 8, 2019
Versões Antigas
Bug fixes
Show More
Version History
1.6.3
Aug 8, 2019
Bug fixes
1.6.2
Aug 2, 2019
Bug fixes
1.6.1
Sep 27, 2018
This update contains bug fixes and new features such as Feedback tools, public access to BI Press Releases, an integrated canteen menu for locations in Germany and the addition of HR local news.

BI News FAQ

Clique aqui para saber como baixar BI News em um país ou região restrita.
Confira a lista a seguir para ver os requisitos mínimos de BI News.
iPhone
iPad
BI News suporta Dutch, English

Alternativa de BI News

Você pode gostar

Obtenha mais de Boehringer Ingelheim Pharma GmbH & Co.KG